Eutilex signed an MOU with Medirama, specializing in clinical consulting, to develop and commercialize strategic new drugs.

The two companies will maximize synergy in the overall development of new drugs, such as discovering additional candidates for Eutilex’s cell therapy and dual antibody therapy, conducting non-clinical and clinical development, and preparing global business development strategies, Eutilex said Wednesday.

“Combining the strengths of the two companies, we will strive to come up with an optimal strategy for accelerating global clinical and business development.” Eutilex CEO Choi Soo-young said,

Medirama CSO Moon Han-lim also said, “Based on our accumulated know-how, we will fully support the global clinical development of the Eutilex’s immunotherapy platform,”

Medirama is a contract development and research organization (CDRO) co-founded by top experts in clinical development. CSO Moon has worked at global multinational pharmaceutical companies like GSK, Sanofi Aventis, and Mundipharma. He is regarded as one of the best experts in the clinical development of anticancer drugs.

Last September, Eutilex said it recruited Moon as an advisor to receive his consulting for the entire clinical trial ranging from design to execution of each pipeline.